GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » FCF Margin %

BCTX (BriaCell Therapeutics) FCF Margin % : 0.00% (As of Jul. 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BriaCell Therapeutics's Free Cash Flow for the three months ended in Jul. 2024 was $-4.04 Mil. BriaCell Therapeutics's Revenue for the three months ended in Jul. 2024 was $0.00 Mil. Therefore, BriaCell Therapeutics's FCF Margin % for the quarter that ended in Jul. 2024 was 0.00%.

As of today, BriaCell Therapeutics's current FCF Yield % is -99.15%.

The historical rank and industry rank for BriaCell Therapeutics's FCF Margin % or its related term are showing as below:


BCTX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

BriaCell Therapeutics FCF Margin % Historical Data

The historical data trend for BriaCell Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics FCF Margin % Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BriaCell Therapeutics's FCF Margin %

For the Biotechnology subindustry, BriaCell Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's FCF Margin % falls into.


BriaCell Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BriaCell Therapeutics's FCF Margin for the fiscal year that ended in Jul. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Jul. 2024 )/Revenue (A: Jul. 2024 )
=-24.583/0
= %

BriaCell Therapeutics's FCF Margin for the quarter that ended in Jul. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Jul. 2024 )/Revenue (Q: Jul. 2024 )
=-4.036/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » FCF Margin %
Comparable Companies
TSX:ONC TSX:TH XCNQ:DTC TSX:EPRX TSXV:ARCH TSXV:NGEN TSXV:MIR XCNQ:ACOG NEOE:MMED TSX:MBX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
8BT:Germany BCT:Canada
Address
235 - 15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
Website
https://www.briacell.com
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0